Category Business

2019-2024 Pharma Collaboration Report: Upfront, Milestones, Royalties by Company, Therapy, Tech – ResearchAndMarkets.com

The “Collaboration Deals in Pharmaceuticals 2019-2024” report is now available on ResearchAndMarkets.com. This report offers a detailed analysis of collaboration deals in the pharmaceutical industry, explaining why and how companies enter these deals. Updated to include data from 2019 to…

Read More2019-2024 Pharma Collaboration Report: Upfront, Milestones, Royalties by Company, Therapy, Tech – ResearchAndMarkets.com

Unprecedented Opportunities: 265+ Collaborative and Licensing Deals in In-Vitro Diagnostics

The ‘In Vitro Diagnostic Collaboration and Licensing Deals 2016-2024’ report offers an extensive analysis and unprecedented access to collaboration and licensing agreements in the global biopharma industry. Updated and meticulously compiled, this report delves into the intricate details of over…

Read MoreUnprecedented Opportunities: 265+ Collaborative and Licensing Deals in In-Vitro Diagnostics

Sipavibart EMA Regulatory Submission Approved for Accelerated Assessment in COVID-19 Prevention

AstraZeneca’s Marketing Authorisation Application (MAA) for sipavibart has been accepted under the accelerated assessment procedure by the European Medicines Agency (EMA) for the pre-exposure prophylaxis (prevention) of COVID-19 in immunocompromised patients. Sipavibart is an investigational long-acting antibody designed to provide…

Read MoreSipavibart EMA Regulatory Submission Approved for Accelerated Assessment in COVID-19 Prevention

Audrey Duval Derveloy Named Global Head of Corporate Affairs, Joins Sanofi Executive Committee

Audrey Duval Derveloy Appointed Global Head of Corporate Affairs at Sanofi Audrey Duval Derveloy, a seasoned leader in the healthcare industry and current President of Sanofi France, has been appointed Executive Vice President and Global Head of Corporate Affairs at…

Read MoreAudrey Duval Derveloy Named Global Head of Corporate Affairs, Joins Sanofi Executive Committee

EU Approves Truqap Plus Faslodex for Advanced ER-Positive Breast Cancer Treatment

AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has received approval from the European Union (EU) for treating adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer that harbors one or more PIK3CA, AKT1, or PTEN…

Read MoreEU Approves Truqap Plus Faslodex for Advanced ER-Positive Breast Cancer Treatment

Presentation of New SEQUOIA Study Findings: BRUKINSA® and Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global leader in oncology, has unveiled new findings from the SEQUOIA study of BRUKINSA® (zanubrutinib) today at EHA2024 in Madrid, Spain. The presentation highlighted results from arm D, exploring BRUKINSA in…

Read MorePresentation of New SEQUOIA Study Findings: BRUKINSA® and Venetoclax in High-Risk First-Line CLL/SLL at EHA2024